Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease.
Bonig H, Verbeek M, Herhaus P, Braitsch K, Beutel G, Schmid C, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann LM, Jahrsdörfer B, Schrezenmeier H, Kuci S, Kuci Z, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P.
Bonig H, et al. Among authors: verbeek m.
J Transl Med. 2024 Jun 13;22(1):566. doi: 10.1186/s12967-024-05348-8.
J Transl Med. 2024.
PMID: 38872104
Free PMC article.
No abstract available.